The quest to eliminate dormant HIV infections represents one of medicine's most challenging puzzles, potentially transforming millions of lives worldwide. Current antiretroviral therapy successfully suppresses active viral replication but cannot reach the hidden viral DNA integrated into memory T cells, creating permanent reservoirs that persist for decades.
This comprehensive review examines emerging "shock and kill" strategies designed to force latent HIV out of hiding before destroying it. Laboratory studies demonstrate that compounds like vorinostat and disulfiram can reactivate dormant viruses in CD4+ T cells, while histone methyltransferase inhibitors and protein kinase C activators show similar wake-up effects. Immunotherapy approaches aim to enhance the body's natural ability to recognize and eliminate reactivated infected cells, potentially completing the eradication process.
These findings represent significant laboratory progress, but translating cellular models into clinical reality remains formidable. Previous attempts to purge HIV reservoirs have largely failed in human trials, despite promising laboratory results. The virus's ability to establish sanctuary sites in tissues with poor drug penetration, combined with the extreme sensitivity required to detect and eliminate every last infected cell, creates nearly insurmountable technical challenges. Current approaches may reduce reservoir size without achieving complete elimination, potentially requiring combination strategies targeting multiple pathways simultaneously. While these therapeutic advances offer genuine hope for functional cures, the complexity of HIV latency suggests that a world free of HIV infection likely remains years away, requiring breakthrough innovations beyond current shock-and-kill paradigms.